University of Kentucky Markey Cancer Center - Cancer Center Support Grant

描述(申请人提供)：Markey癌症中心(MCC)是一个专门的基质癌症中心，是肯塔基大学(英国)和英国医疗保健企业不可分割的一部分，近年来在MCC主任B.Mark Evers博士的领导下经历了戏剧性的扩张。在中心发展的这一阶段，MCC通过国家癌症研究所(NCI)癌症中心支持赠款寻求支持，以利用这一势头，通过癌症研究、预防和患者护理的综合计划，推动肯塔基州，特别是阿巴拉契亚肯塔基州的癌症死亡率显著降低。在一个多项癌症指标处于全国领先地位的州，对NCI癌症中心命名的需求尤其迫切，其中包括全国最高的癌症死亡率。MCC坐落在一个校园里，所有六所卫生职业学院都在附近，MCC提供了丰富的跨学科历史 合作是一项杰出的癌症预防和控制计划，已在阿巴拉契亚肯塔基州产生了开创性的工作，在癌症生物学、DNA修复和氧化应激方面获得全国赞誉的基础研究计划，以及由顶尖的五所药学院补充的翻译治疗计划。 这些优势汇聚在MCC的四个主题研究项目中：癌细胞生物学和信号；癌症预防和控制；药物发现、输送和转译治疗；以及氧化还原损伤和修复。目前，MCC的108名研究和助理研究成员在全校7所学院的24个系任职(过去3年中招聘了25名新教师)。MCC成员为144个研究项目提供资助，每年的综合(直接+间接)金额超过3,050万美元，其中超过1,130万美元(37%)来自NCI。治疗临床试验的收益在三年内增加了130%，MCC可分配空间增加了40%，包括最先进的研究空间翻了一番。此外，六个共享资源通过为专门知识和先进方法提供强大的基础设施，为尖端研究提供便利。它们包括：生物样品和组织采购；生物统计学；癌症研究信息学；临床研究和数据管理；流式细胞术和细胞分类；以及癌症中的自由基生物学。MCC目前处于有利地位，能够接受新的挑战，并继续朝着最大限度地利用这些优势的关键战略方向发展。

DESCRIPTION (provided by applicant): The Markey Cancer Center (MCC), a dedicated matrix cancer center established as an integral part of the University of Kentucky (UK) and the UK Healthcare enterprise, has undergone dramatic expansion in recent years under the leadership of MCC Director Dr. B. Mark Evers. At this point in the center's development, the MCC seeks support through the National Cancer Institute (NCI) Cancer Center Support Grant to capitalize on this momentum and to drive a measurable reduction in cancer mortality in Kentucky, particularly Appalachian Kentucky, through a comprehensive program of cancer research, prevention, and patient care. The need for NCI Cancer Center designation is particularly acute in a state that leads the nation across numerous cancer indicators, including the highest rate of cancer deaths in the nation. Situated on a campus with all six health professions colleges in proximity to each other, the MCC offers a history of rich transdisciplinary collaboration, an outstanding program of cancer prevention and control that has produced seminal work in Appalachian Kentucky, nationally acclaimed basic research programs in cancer biology and DNA repair and oxidative stress, and a translational therapeutics program complemented by a top five College of Pharmacy. These strengths have coalesced in MCC's four thematic research programs: Cancer Cell Biology and Signaling; Cancer Prevention and Control; Drug Discovery, Delivery and Translational Therapeutics; and Redox Injury and Repair. Currently, the MCC's 108 Research and Associate Research members hold appointments in 24 departments in 7 colleges across the university (25 new faculty were recruited in the last 3 years). MCC members hold grants for 144 research projects funded in the annual composite (direct + indirect) amount of more than $30.5 million, of which over $11.3 million (37%) comes from the NCI. Accrual to therapeutic clinical trials has increased over 130% in three years, and MCC assignable space has increased 40%, including a doubling of state-of-the-art research space. In addition, six shared resources facilitate cutting-edge research by providing a robust infrastructure for specialized expertise and advanced methods. They include: Biospecimen and Tissue Procurement; Biostatistics; Cancer Research Informatics; Clinical Research and Data Management; Flow Cytometry and Cell Sorting; and Free Radical Biology in Cancer. The MCC is currently well positioned to take on new challenges and to continue to evolve in key strategic directions that take maximum advantage of these strengths.